Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Current status of therapeutic monoclonal antibodies against SARS-CoV-2
Sanjeev Kumar, Anmol Chandele, Amit Sharma
PLoS Pathogens (2021) Vol. 17, Iss. 9, pp. e1009885-e1009885
Open Access | Times Cited: 97

Showing 1-25 of 97 citing articles:

Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern
Laura Vangeel, Winston Chiu, Steven De Jonghe, et al.
Antiviral Research (2022) Vol. 198, pp. 105252-105252
Open Access | Times Cited: 384
Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody
Wanchao Yin, Youwei Xu, Peiyu Xu, et al.
Science (2022) Vol. 375, Iss. 6584, pp. 1048-1053
Open Access | Times Cited: 269
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Yu‐Chyi Hwang, Ruei‐Min Lu, Shih-Chieh Su, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 194
Potential therapeutic options for COVID-19: an update on current evidence
Zahra Niknam, Ameneh Jafari, Ali Golchin, et al.
European journal of medical research (2022) Vol. 27, Iss. 1
Open Access | Times Cited: 136
Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets
Masoumeh Farahani, Zahra Niknam, Leila Mohammadi Amirabad, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 145, pp. 112420-112420
Open Access | Times Cited: 99
Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2
Cyril Planchais, I. Fernández, Timothée Bruel, et al.
The Journal of Experimental Medicine (2022) Vol. 219, Iss. 7
Open Access | Times Cited: 51
Innate and Adaptive Immunity during SARS-CoV-2 Infection: Biomolecular Cellular Markers and Mechanisms
Brent Brown, Vanshika Ojha, Ingo Fricke, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 408-408
Open Access | Times Cited: 37
The rising SARS‐CoV‐2 JN.1 variant: evolution, infectivity, immune escape, and response strategies
Yishan Lu, Danyi Ao, Xuemei He, et al.
MedComm (2024) Vol. 5, Iss. 8
Open Access | Times Cited: 7
Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody
Sanjeev Kumar, Anamika Patel, Lilin Lai, et al.
Science Advances (2022) Vol. 8, Iss. 40
Open Access | Times Cited: 36
In Silico Analyses on the Comparative Potential of Therapeutic Human Monoclonal Antibodies Against Newly Emerged SARS-CoV-2 Variants Bearing Mutant Spike Protein
Nabarun Chandra Das, Pritha Chakraborty, Jagadeesh Bayry, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 35
Monoclonal antibody therapies in the management of SARS-CoV-2 infection
Enrique Míguez‐Rey, Dasom Choi, Seungmin Kim, et al.
Expert Opinion on Investigational Drugs (2022) Vol. 31, Iss. 1, pp. 41-58
Open Access | Times Cited: 35
Predicting Antiviral Resistance Mutations in SARS-CoV-2 Main Protease with Computational and Experimental Screening
Vishnu Mini Sasi, Sven Ullrich, Jennifer Ton, et al.
Biochemistry (2022) Vol. 61, Iss. 22, pp. 2495-2505
Open Access | Times Cited: 34
Approaches to the Potential Therapy of COVID-19: A General Overview from the Medicinal Chemistry Perspective
J. Carlos Menéndez
Molecules (2022) Vol. 27, Iss. 3, pp. 658-658
Open Access | Times Cited: 31
SARS-CoV-2 VOCs, Mutational diversity and clinical outcome: Are they modulating drug efficacy by altered binding strength?
Sheeba Saifi, Varsha Ravi, Sparsh Sharma, et al.
Genomics (2022) Vol. 114, Iss. 5, pp. 110466-110466
Open Access | Times Cited: 29
An Overview of Human Anti-HIV-1 Neutralizing Antibodies against Diverse Epitopes of HIV-1
Sanjeev Kumar, Swarandeep Singh, Kalpana Luthra
ACS Omega (2023) Vol. 8, Iss. 8, pp. 7252-7261
Open Access | Times Cited: 18
COVID-19 clinical presentation, management, and epidemiology: a concise compendium
David P. Maison, Hawi Tasissa, Amelia N. Deitchman, et al.
Frontiers in Public Health (2025) Vol. 13
Open Access
T‐Cell‐Dependent Bispecific IgGs Protect Aged Mice From Lethal SARS‐CoV‐2 Infection
Wenyan Fu, Wei Zhang, Zuhui You, et al.
Advanced Science (2025)
Open Access
Bispecific antibodies targeting the N-terminal and receptor binding domains potently neutralize SARS-CoV-2 variants of concern
Adonis A. Rubio, Viren A. Baharani, Bernadeta Dadonaite, et al.
Science Translational Medicine (2025) Vol. 17, Iss. 788
Closed Access
COVID-19 Drug Development
Seungtaek Kim
Journal of Microbiology and Biotechnology (2021) Vol. 32, Iss. 1, pp. 1-5
Open Access | Times Cited: 36
A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants
Jules B. Weinstein, Timothy A. Bates, Hans C. Leier, et al.
iScience (2022) Vol. 25, Iss. 3, pp. 103960-103960
Open Access | Times Cited: 25
Dual Inhibition of Vacuolar-ATPase and TMPRSS2 Is Required for Complete Blockade of SARS-CoV-2 Entry into Cells
Simoun Icho, Edurne Rujas, Krithika Muthuraman, et al.
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 7
Open Access | Times Cited: 25
Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than Omicron
José M. Casasnovas, Yago Margolles, María A. Noriega, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 24
Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity
Jaime L. Jensen, Rajeshwer S. Sankhala, Vincent Dussupt, et al.
Journal of Virology (2023) Vol. 97, Iss. 7
Open Access | Times Cited: 14
The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19
Aline Almeida-Oliveira, Diana Freire, A. Andrade, et al.
Journal of Pharmaceutical Innovation (2023) Vol. 18, Iss. 3, pp. 1194-1212
Open Access | Times Cited: 11
Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV)
Chamandi S. Dampalla, Matthew J. Miller, Yunjeong Kim, et al.
European Journal of Medicinal Chemistry (2023) Vol. 254, pp. 115376-115376
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top